abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US HQ
2014 Founded
57 Employees
Public company Type
AVIR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
Atea Pharmaceuticals pipeline
Portfolio lens on 29 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Atea Pharmaceuticals drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
bictegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Atea Pharmaceuticals's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 integrase.
- Target
- Human immunodeficiency virus type 1 integrase
- Mechanism
- Human immunodeficiency virus type 1 integrase inhibitor
-
buprenorphine
Nervous system (N07)US regulatory status: approved. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Atea Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Atea Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Atea Pharmaceuticals's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Atea Pharmaceuticals's portfolio.
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.
- Target
- Opioid receptors; mu/kappa/delta
- Mechanism
- Opioid receptors; mu/kappa/delta antagonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
sofosbuvir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: RNA-directed RNA polymerase.
- Target
- RNA-directed RNA polymerase
- Mechanism
- RNA-directed RNA polymerase inhibitor
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Atea Pharmaceuticals in public FDA and regional records.